VAXCYTE INC (PCVX)
US92243G1085 - Common Stock
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX)...
Relative Strength Alert For Vaxcyte
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,...
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Vaxcyte Enters Oversold Territory (PCVX)
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of...
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate...
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaccine Maker Vaxcyte Offers $1 Billion in Shares, Warrants
Vaxcyte Inc., a clinical stage vaccine company, is seeking to raise $1 billion by selling shares and pre-funded warrants after the company reported data from a recent study, sending the stock surging.
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. VAX-31 was well tolerated and demonstrated a safety profile at all doses studied through the full six-month evaluation period, similar to Pfizer Inc's (NYSE:PFE) Prevnar 20 (PCV20). VAX-31 showed robust opsonophagocytic activ
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31...
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vaxcyte, Inc. (NASDAQ: PCVX) on behalf of the company's shareholders. The...
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
Vaxcyte Larger Than S&P 500 Component Federal Realty Investment Trust
Vaxcyte Appoints John Furey to Board of Directors
Vaxcyte Appoints John Furey to Board of Directors
Vaxcyte appoints John Furey to Board of Directors. ...
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxcyte (NASDAQ:PCVX) just reported results for the first quarter of 2024.Vaxcy...